FLT3 and acute myeloid leukemia: Importantly for IB monotherapy and the IB/pimozide combination, no drug resistance was observed for FLT3/ITD+ cell lines with acquired TKD mutations, indicating that IB and IB/pimozide may be able to overcome this substantial hurdle to FLT3/ITD+ AML treatment.